Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

[1]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[2]  D. Stuart,et al.  Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.

[3]  Graham W. Taylor,et al.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.

[4]  H. Jäck,et al.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.

[5]  A. Griffiths,et al.  SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms , 2021, Cell.

[6]  A. Kelleher,et al.  Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection , 2021, Cell Reports Medicine.

[7]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[8]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[9]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[10]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization , 2021, bioRxiv.

[11]  D. Stuart,et al.  Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera , 2021, Cell.

[12]  R. Rappuoli,et al.  Extremely potent human monoclonal antibodies from COVID-19 convalescent patients , 2021, Cell.

[13]  D. Stuart,et al.  Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera , 2021, Cell.

[14]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection , 2021, Cell.

[15]  R. Paredes,et al.  Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes , 2021, Med.

[16]  Gregory M. Goldgof,et al.  Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Gregory M. Goldgof,et al.  Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[19]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[20]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[21]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection , 2020, bioRxiv.

[22]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[23]  A. Iafrate,et al.  COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.

[24]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[25]  L. Carter,et al.  Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.

[26]  I. Wilson,et al.  Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity , 2020, Immunity.

[27]  M. Nussenzweig,et al.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.

[28]  Sarah K. Hilton,et al.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, Cell Host & Microbe.

[29]  A. Meola,et al.  Maturation and persistence of the anti-SARS-CoV-2 memory B cell response , 2020, Cell.

[30]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to eight months after infection , 2020, bioRxiv.

[31]  M. Nussenzweig,et al.  SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.

[32]  I. Wilson,et al.  Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies , 2020, Biochemical and Biophysical Research Communications.

[33]  G. Atwal,et al.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.

[34]  A. Iafrate,et al.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.

[35]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[36]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[37]  Sarah K. Hilton,et al.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.

[38]  L. Carter,et al.  Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.

[39]  I. Wilson,et al.  Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity , 2020, bioRxiv.

[40]  Guozhong Zhang,et al.  Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 , 2020, Signal Transduction and Targeted Therapy.

[41]  C. Reusken,et al.  Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections , 2020, The Journal of infectious diseases.

[42]  S. Hoffman,et al.  Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. , 2020, Cell host & microbe.

[43]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[44]  Jesse D. Bloom,et al.  Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding , 2020, bioRxiv.

[45]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[46]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[47]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[48]  Gregory M. Goldgof,et al.  Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity , 2020, medRxiv.

[49]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[50]  A. Manenti,et al.  Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples , 2020, Journal of medical virology.

[51]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[52]  K. Ishii,et al.  Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies , 2019, Nature Communications.

[53]  T. Kurosaki,et al.  Whole-Virion Influenza Vaccine Recalls an Early Burst of High-Affinity Memory B Cell Response through TLR Signaling , 2016, The Journal of Immunology.

[54]  T. Kurosaki,et al.  Memory B cells , 2015, Nature Reviews Immunology.

[55]  Michael Meyer-Hermann,et al.  Germinal center B cells govern their own fate via antibody feedback , 2013, The Journal of experimental medicine.

[56]  M. Clark,et al.  Germinal Center B-cells , 2012, Autoimmunity.

[57]  Y. Matsuura,et al.  Involvement of Ceramide in the Propagation of Japanese Encephalitis Virus , 2010, Journal of Virology.

[58]  C. Pannuti,et al.  Use of an Immunoglobulin G Avidity Test To Discriminate between Primary and Secondary Dengue Virus Infections , 2004, Journal of Clinical Microbiology.

[59]  Kenneth G. C. Smith,et al.  The extent of affinity maturation differs between the memory and antibody‐forming cell compartments in the primary immune response , 1997, The EMBO journal.

[60]  J. Cohen.  What are the correlates of protection? , 1993, Science.

[61]  H. Eisen,et al.  VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. , 1964, Biochemistry.

[62]  COVID-19 Genomics UK (COG-UK) Consortium Report Number 6 , 2020 .

[63]  M. Nussenzweig,et al.  Dopamine in germinal centers , 2017, Nature Immunology.

[64]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[65]  G W Siskind,et al.  Cell selection by antigen in the immune response. , 1969, Advances in immunology.